Skip to content
thestock.space

On 6 Nov 2026, Orchid Pharma was priced at ₹868.00, or 539.1× trailing earnings, against an industry P/E of 28.7×, and the shares are 24% below their 52-week high. Sales grew 22% a year over 3 years while net profit fell 40%, with ROCE of 1.1% and ROE of 0.6%. Debt is 0.28× equity. It is a small-cap company with a market cap of ₹4,402 Cr, ranked 45th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 14% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹896.75
Day high
₹896.75
Day low
₹862.55
Prev. close
₹902.15
Volume
31.4K

Health check

3 fair · 3 to check
  • ReturnsIn line

    +14.1% over a year, better than 3 of 7 peers.

  • Price tagPricier

    P/E 539.1 vs industry 28.7.

  • GrowthSteady

    Sales +22.3%, profit −40.1% a year over 3 years.

  • ProfitabilityWeak

    ROCE 1.1% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.28× equity, interest covered 2.2×.

  • Red flags3 to check

    Return on equity is low at 0.6%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹4,402 Cr, #45 of 154 in its industry by size.

Defensive

Beta 0.56 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹852 Cr · profit ₹29 Cr
Market cap
₹4,402 Cr
Small cap
P/E
539.1
Industry 28.7
Price to book
3.42
Peers 4.99
Dividend yield
0.00%
ROE
0.6%
Peers 14.7%
ROCE
1.1%
Peers 17.9%
Debt to equity
0.28
Debt ₹363 Cr
EPS (TTM)
₹1.61
Face value ₹10
OPM (TTM)
5.0%
Net margin 3.5%
Sales growth
+15.6%
Latest quarter vs a year ago
Profit growth
−81.6%
Latest quarter vs a year ago
Price to sales
5.17
EV/EBITDA 90.0

Strengths and risks

Strengths

  • Quarterly sales up 15.6% on a year ago.
  • Positive operating cash flow in each of the last 4 years.
  • Promoter stake up from 69.8% to 74.5%.

Risks to check

  • Return on equity is low at 0.6%.
  • Quarterly profit down 81.6% on a year ago.
  • P/E of 539.1 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Orchid Pharma

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins and injectable cephalosporins; human and veterinary products; and antibiotics, including beta-lactam. It serves pharma companies, generic drug manufacturers,…

Headquarters
Chennai
Employees
1,169
Sector
Healthcare
ISIN
INE191A01027
Website
orchidpharma.com

Price range

52 weeks

₹480.00₹1,143.50

Today

₹862.55₹896.75
Avg volume (3M)
99.5K
1-year return
plus 14.1%
From 52-week high
minus 24.1%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
ORCHPHARMAOrchid Pharma868.00minus 3.79%4,402539.13.42–0.6%12.5%22.3%−40.1%0.00%plus 14.1%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
263194207238304
269195207203290
−5.6−1.50.134.714
−2.1%−0.8%0.0%14.6%4.6%
11.610.87.1−0.51.8
2.33.73.23.12.2
10.58.998.910.9
––−7.10.5–
−6.9−3.3−12.122.82.6
–––0.0%2.7%
−5.7−5.7−12.623.83.2
-0.95-1.13-2.494.690.54

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+22.3%
Profit CAGR 3Y
−40.1%
EPS CAGR 3Y
−47.3%
ROE
0.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6668191,3891,217
–+23.0%+69.5%minus 12.4%
5817071,2221,155
84.511216762.7
12.7%13.6%12.0%5.1%
17.830.526.135.8
32.216.412.89
54.833.24243.2
40−0.7−16.8−35.8
55.291.912210.4
–−3.4%−7.9%−1.8%
46.392.213510
–+99.0%+46.6%minus 92.6%
11.3519.0622.551.66

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
40.850.759.959.9
6481,1191,4941,504
331135154307
205249370388
1,2251,5542,0772,258
6216458341,122
48.525.5127430
44.48.9−42.8−39.1
27.54.521.27.1
4848701,139738
1,2251,5542,0772,258

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
18.312651.4126
−31.2−312−36.5−277
31.21672.5137
18.3−1917.3−14.1
−84.9−64.8−154−390
−66.661.2−102−264

Shareholding pattern

Source: NSE filings
74.5%
promoters
  • Promoters74.45%
  • Public25.55%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202674.45%25.55%0.00
1 Aug 202674.45%25.55%plus 4.61
30 Jun 202669.84%30.16%0.00
31 Mar 202669.84%30.16%0.00
31 Dec 202569.84%30.16%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you